Syros Pharmaceuticals Inc. (NASDAQ:SYRS) received a $20.00 price target from equities researchers at Piper Jaffray Cos. in a research report issued to clients and investors on Monday. The firm presently has a a “buy” rating on the stock. Piper Jaffray Cos.’s target price would indicate a potential upside of 50.15% from the stock’s current price.

Several other analysts also recently issued reports on the stock. HC Wainwright started coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 18th. They issued a “neutral” rating and a $10.00 price target for the company. Cowen and Company initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, July 25th. They issued an “outperform” rating for the company. JMP Securities initiated coverage on shares of Syros Pharmaceuticals in a report on Monday, July 25th. They set an “outperform” rating and a $22.00 price objective on the stock. Zacks Investment Research raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, October 20th. Finally, Wedbush reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Syros Pharmaceuticals in a report on Monday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Syros Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $17.50.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Shares of Syros Pharmaceuticals (NASDAQ:SYRS) opened at 13.32 on Monday. Syros Pharmaceuticals has a 52-week low of $8.16 and a 52-week high of $21.50. The firm’s 50-day moving average is $13.60 and its 200 day moving average is $13.05. The company’s market capitalization is $311.34 million.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by $0.11. On average, equities research analysts anticipate that Syros Pharmaceuticals will post ($2.98) earnings per share for the current year.

Institutional investors have recently bought and sold shares of the company. Aisling Capital LLC purchased a new position in Syros Pharmaceuticals during the second quarter worth about $16,490,000. Deerfield Management Co. acquired a new stake in Syros Pharmaceuticals during the second quarter worth approximately $38,028,000. Weiss Multi Strategy Advisers LLC acquired a new stake in Syros Pharmaceuticals during the second quarter worth approximately $832,000. Flagship Ventures Fund IV General Partner LLC acquired a new stake in Syros Pharmaceuticals during the second quarter worth approximately $87,241,000. Finally, Redmile Group LLC acquired a new stake in Syros Pharmaceuticals during the second quarter worth approximately $15,058,000. 54.63% of the stock is currently owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.